Tumor Lysis Syndrome is a response to cancer treatment that occurs when cancer cells release large amounts of phosphate, potassium, and nucleic acids into the bloodstream after they die. Tumor Lysis Syndrome is often accompanied by hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and acute renal failure. Individuals with acute leukemia are most at risk, and symptoms may develop immediately or within 48 hours of the cancer treatment. High-risk patients are identified before receiving cancer treatment and are provided with preventative therapy. Patients are carefully watched during the 48 hour period after their treatment, because early detection of Tumor Lysis Syndrome is essential to prevent kidney damage or fatality. Tumor Lysis Syndrome is treated by flushing out excess potassium using a diuretic or kidney dialysis.
Tumor Lysis Syndrome Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Tumor Lysis Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 2941 products for the study of Tumor Lysis Syndrome that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.